Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by mollevi
Last modified by Nathalie Bonnefoy
Group name EquipeNB
Item Type Journal Article
Title [Stereotactic body radiotherapy for liver tumors: State of the art]
Creator Riou et al.
Author O. Riou
Author D. Azria
Author F. Mornex
Abstract Thanks to the improvement in radiotherapy physics, biology, computing and imaging, patients presenting with liver tumors can be efficiently treated by radiation. Radiotherapy has been included in liver tumors treatment guidelines at all disease stages. Liver stereotactic radiotherapy has to be preferred to standard fractionated radiotherapy whenever possible, as potentially more efficient because of higher biological equivalent dose. Liver stereotactic radiotherapy planning and delivery require extensive experience and optimal treatment quality at every step, thus limiting its availability to specialized centres. Multicentre studies are difficult to develop due to a large technical heterogeneity. Respiratory management, image guidance and immobilization are considerations as important as machine type. The use of multimodal planning imaging is compulsory to achieve expected contouring quality. Treatment efficacy is difficult to assess following liver stereotactic radiotherapy, but local control is high and toxicity unusual. As a consequence, liver stereotactic radiotherapy is part of multimodal and multidisciplinary management of liver tumors.
Publication Cancer Radiother
Date Sep 06 2017
Journal Abbr Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
DOI 10.1016/j.canrad.2017.07.040
ISSN 1769-6658 (Electronic) 1278-3218 (Linking)
Tags first-last-corresponding, review
Date Added 2018/11/14 - 12:04:32
Date Modified 2019/05/28 - 21:40:28
Notes and Attachments (Note)
(Note)
28888744 (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés